On November 6, the WTO’s Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreed to extend a waiver, allowing the 48 least developed countries (LDCs) not to enforce intellectual property (IP) rights on pharmaceutical products until 2033. The original deadline expires on January 1, 2016.
In June 2013, a general waiver exempting LDCs from the obligation to enforce IP rights was extended to 2021. However, as TRIPS constitutes a separate agreement on public health, LDCs are required to apply for the pharma extension separately. That’s why Bangladesh, on behalf of the LDC member countries, submitted a request to the WTO in February for extending the 2016 deadline for as long as they remain an LDC.
The latest extension, the second specifically applied to pharmaceutical products for LDCs, is in line with directions set by WTO ministers in the 2001 Doha Declaration on the TRIPS Agreement and Public Health. It also follows the adoption of the new UN Sustainable Development Goals (SDGs), which affirm the right of developing countries to utilise TRIPS Agreement flexibilities to ensure access to medicines for all.
LDCs are the poorest and most vulnerable segment of the international community, characterised by very low per capita income, weak human resources, and economic vulnerability, in addition to inherent geographical and environmental constraints. Not surprisingly, their productive capacity is highly limited by severe infrastructure deficits.
For nearly a billion people living in the LDCs, access to health care and modern medicine remains a major challenge. According to the UN, more than 70% of the LDC population lives on less than $2 per day, and an estimated 252 million people live with hunger. It is critically important to exempt these poor countries from IP obligation in order to provide access to affordable treatment for scores of diseases. Thus LDCs’ request for a pharmaceutical transition period for as long as they remain LDCs was not only relevant and valid, it was based on strong humanitarian grounds.
The 2001 Doha Declaration exempted LDCs from pharmaceutical product patenting until January 1, 2016, which has significantly improved access to affordable treatments in the poorest nations. This flexibility largely enabled LDC governments, donors, and the international community to treat more patients with HIV/AIDs and many other diseases which would not be possible in presence of strict patent enforcement.
Besides scores of infectious and communicable diseases, LDCs now have increasing prevalence of non-communicable diseases such as cancer, arthritis, diabetes, etc. In the absence of health insurance in these poor countries, most of the health care related expenses are out-of-pocket and no way affordable to the patients.
Patent protection significantly contributes to high costs, making critical treatments unaffordable to patients in poor nations. In numerous communications, civil society organisations have highlighted the critical importance of this exemption from pharmaceutical patents and test data protection and this was unequivocally supported by European Union, UN, and other international agencies, NGOs, and suppliers of generic medicines from across the world.
Medicine price in Bangladesh is among the lowest in the world and that has been possible because the country has much competitive generic drug skills, and it doesn’t have to pay royalty to innovators for producing patented medicines. For example, cholesterol lowering drug Crestor 10mg (rosuvastatin) tablet costs around $7.25 in the US versus a comparable Bangladeshi generic price of $0.25 while diabetes drug Januvia 50mg (sitagliptin) is priced at $11.25 against the local generic price of $0.25.
Bangladesh has recently introduced the generic version of revolutionary hepatitis C drugs Sovaldi (sofosbuvir) and Harvoni (sofosbuvir+ledipasvir) which are available locally at $6.5 and $13 per tablet compared to the originator brands at $1,000 and $1,125 respectively.
For a poor country like Bangladesh, with one of the lowest per capita health care expenditures in the world, it would be impossible to afford such expensive medicines, had they not been manufactured in the country. Like these revolutionary drugs, there are a number of patented biological drugs for chronic diseases and cancer, which may be produced in the country and made accessible to the people.
Pharma is largely a knowledge-driven and technology-intensive industry, and this requires significant investment in R&D as well as infrastructure compared to other industries. Pharma’s success mostly depends on its intellectual capital where special skill-sets are required to deal with every stage of its operations. Bangladesh has a more organised pharma industry compared to any other LDC members.
Since the promulgation of the National Drug Policy in 1982 the country has made considerable progress in terms of generic drug skills and infrastructure. Currently, 97% of country’s demand is met by domestic manufacturers. Leading pharma companies have already secured accreditations from major drug regulatory authorities, and today, Bangladeshi medicine are also being exported to many countries in the world.
However, the industry is still faced with many long-standing challenges. Lack of sufficient backward integration into active pharmaceutical ingredients, or APIs, remains a major challenge for us. The industry is still heavily dependent on import for raw material to produce medicines. The competitiveness in the generic drug industry largely depends on API backward linkage.
The industry also needs to have important infrastructures such as a central bioequivalence centre, state of the art drug testing labs, advanced pharmaceutical research centre, FDA-like strong regulatory authority, etc. In addition, we too focus on capacity-building in IP and legal affairs and strengthen our patent office as they are increasingly becoming important for operating in the generic drug space.
As of now, there is no special economic zone for pharma to provide an internationally competitive and hassle-free environment. The industry also needs to find new opportunities of growth in contract manufacturing and research, clinical research, and custom synthesis.
Thus, only competitive labour cost is not enough for this industry, and much needs to be done for the country to operate across the pharma value chain and to establish a strong technological base. This additional 17-year IP waiver would definitely help the industry address many of these challenges, and equip itself to be more competitive in the future in order to provide affordable medicine for this large disadvantaged population.
It’s quite regrettable that, although the 2001 Doha declaration allowed us pharma patent waiver till 2015, we could not utilise the flexibility to develop our infrastructure such as API technology park etc, which would give the industry a tremendous boost in gaining further competitiveness. This time, we must make no mistake in getting our act together.
Even though Bangladesh is likely to graduate to middle income status well ahead of 2033, we must make the best use of the time period available, and actively use the created policy space it provides.